Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues

American Journal of Physiology-Renal Physiology
1996.0

Abstract

To see whether P-glycoprotein (PGP) expressed in renal brush-border membranes (BBM) could interact with compounds known as modulators of multidrug resistance (MDR), photoaffinity-labeling experiments were performed. A 145k-Da protein was photolabeled with [125I] iodoarylazidoprazosin, and this labeling was reduced in the presence of cyclosporin A (CsA) and PSC-833 (PSC). Interaction of CsA with PGP was further investigated by treating rats with daily subcutaneous injections of CsA (10 mg.kg-1.day-1). After this treatment, PGP expression levels were dramatically increased in renal BBM, intestine, liver, and many other tissues except the brain. This induction was a reversible process, since after cessation of CsA administration PGP levels declined to reach values similar to those of the control groups. The increase in PGP expression in the kidney was also detected in photolabeling experiments, suggesting the induction of a functional PGP. A higher dose of CsA (50 mg/kg) given as a bolus injection did not modify PGP expression] in renal BBM. These results demonstrate that CsA induces reversible overexpression of PGP in the rat. This may present significant relevance in the design of clinical trials using CsA as a chemosensitizing agent.

Knowledge Graph

Similar Paper

Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues
American Journal of Physiology-Renal Physiology 1996.0
Human P-glycoprotein transports cyclosporin A and FK506.
Journal of Biological Chemistry 1993.0
Cyclosporins:  Structure−Activity Relationships for the Inhibition of the Human MDR1 P-Glycoprotein ABC Transporter
Journal of Medicinal Chemistry 2002.0
Influence of Different Chemicals on MDR-1 P-Glycoprotein Expression and Activity in the HK-2 Proximal Tubular Cell Line
Toxicology and Applied Pharmacology 2002.0
Inhibitory Effects of a Cyclosporin Derivative, SDZ PSC 833, on Transport of Doxorubicin and Vinblastine via Human P‐Glycoprotein
Japanese Journal of Cancer Research 1998.0
Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo correlation
British Journal of Pharmacology 1996.0
Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*
Clinical Pharmacology & Therapeutics 1997.0
Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
Journal of Clinical Investigation 1995.0
Interaction of Imatinib Mesilate with Human P-Glycoprotein
The Journal of Pharmacology and Experimental Therapeutics 2003.0
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies
Biochemical and Biophysical Research Communications 2004.0